Malcolm Boyce1, Andrew R Moore2, Liv Sagatun3, Bryony N Parsons2, Andrea Varro2, Fiona Campbell4, Reidar Fossmark3, Helge L Waldum3, D Mark Pritchard2. 1. Hammersmith Medicines Research, Cumberland Avenue, London, NW10 7EW, UK. 2. Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool, L69 3GE, UK. 3. Department of Gastroenterology and Hepatology, St. Olav's Hospital, and the Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. 4. Department of Pathology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, L7 8XP, UK.
Abstract
AIMS: Netazepide, a gastrin/cholecystokinin 2 receptor antagonist, once daily for 12 weeks reduced the number of tumours and size of the largest one in 16 patients with autoimmune chronic atrophic gastritis (CAG), achlorhydria, hypergastrinaemia and multiple gastric neuroendocrine tumours (type 1 gastric NETs), and normalized circulating chromogranin A (CgA) produced by enterochromaffin-like cells, the source of the tumours. The aim was to assess whether longer-term netazepide treatment can eradicate type 1 gastric NETs. METHODS: After a mean 14 months off netazepide, 13 of the 16 patients took it for another 52 weeks. Assessments were: gastroscopy; gene-transcript expression in corpus biopsies using quantitative polymerase chain reaction; blood CgA and gastrin concentrations; and safety assessments. RESULTS: While off-treatment, the number of tumours, the size of the largest one, and CgA all increased again. Netazepide for 52 weeks: cleared all tumours in 5 patients; cleared all but one tumour in one patient; reduced the number of tumours and size of the largest one in the other patients; normalized CgA in all patients; and reduced mRNA abundances of CgA and histidine decarboxylase in biopsies. Gastrin did not increase further, confirming that the patients had achlorhydria. Netazepide was safe and well tolerated. CONCLUSIONS: A gastrin/cholecystokinin 2 receptor antagonist is a potential medical and targeted treatment for type 1 gastric NETs, and an alternative to regular gastroscopy or surgery. Treatment should be continuous because the tumours will regrow if it is stopped. Progress can be monitored by CgA in blood or biomarkers in mucosal biopsies.
AIMS: Netazepide, a gastrin/cholecystokinin 2 receptor antagonist, once daily for 12 weeks reduced the number of tumours and size of the largest one in 16 patients with autoimmune chronic atrophic gastritis (CAG), achlorhydria, hypergastrinaemia and multiple gastric neuroendocrine tumours (type 1 gastric NETs), and normalized circulating chromogranin A (CgA) produced by enterochromaffin-like cells, the source of the tumours. The aim was to assess whether longer-term netazepide treatment can eradicate type 1 gastric NETs. METHODS: After a mean 14 months off netazepide, 13 of the 16 patients took it for another 52 weeks. Assessments were: gastroscopy; gene-transcript expression in corpus biopsies using quantitative polymerase chain reaction; blood CgA and gastrin concentrations; and safety assessments. RESULTS: While off-treatment, the number of tumours, the size of the largest one, and CgA all increased again. Netazepide for 52 weeks: cleared all tumours in 5 patients; cleared all but one tumour in one patient; reduced the number of tumours and size of the largest one in the other patients; normalized CgA in all patients; and reduced mRNA abundances of CgA and histidine decarboxylase in biopsies. Gastrin did not increase further, confirming that the patients had achlorhydria. Netazepide was safe and well tolerated. CONCLUSIONS: A gastrin/cholecystokinin 2 receptor antagonist is a potential medical and targeted treatment for type 1 gastric NETs, and an alternative to regular gastroscopy or surgery. Treatment should be continuous because the tumours will regrow if it is stopped. Progress can be monitored by CgA in blood or biomarkers in mucosal biopsies.
Authors: J Dinesh Kumar; Islay Steele; Andrew R Moore; Senthil V Murugesan; Zoltan Rakonczay; Viktoria Venglovecz; D Mark Pritchard; Rodney Dimaline; Laszlo Tiszlavicz; Andrea Varro; Graham J Dockray Journal: Am J Physiol Gastrointest Liver Physiol Date: 2015-05-14 Impact factor: 4.052
Authors: Kathryn S Rice; Graeme Dickson; Mark Lane; Jackie Crawford; Seo-Kyung Chung; Mark I Rees; Andrew N Shelling; Donald R Love; Jonathan R Skinner Journal: Heart Rhythm Date: 2010-11-30 Impact factor: 6.343
Authors: A D Higham; L A Bishop; R Dimaline; C G Blackmore; A C Dobbins; A Varro; D G Thompson; G J Dockray Journal: Gastroenterology Date: 1999-06 Impact factor: 22.682
Authors: Tom C Martinsen; Shiro Kawase; Rolf Håkanson; Sverre H Torp; Reidar Fossmark; Gunnar Qvigstad; Arne K Sandvik; Helge L Waldum Journal: Carcinogenesis Date: 2003-08-29 Impact factor: 4.944
Authors: Andrew R Moore; Malcolm Boyce; Islay A Steele; Fiona Campbell; Andrea Varro; D Mark Pritchard Journal: PLoS One Date: 2013-10-01 Impact factor: 3.240
Authors: Julian A Abrams; Armando Del Portillo; Caitlin Hills; Griselda Compres; Richard A Friedman; Bin Cheng; John Poneros; Charles J Lightdale; Rachel De La Rue; Massimiliano di Pietro; Rebecca C Fitzgerald; Antonia Sepulveda; Timothy C Wang Journal: Cancer Prev Res (Phila) Date: 2021-03-29
Authors: Taíssa Maíra Thomaz Araújo; Williams Fernandes Barra; André Salim Khayat; Paulo Pimentel de Assumpção Journal: Chin J Cancer Res Date: 2017-04 Impact factor: 5.087
Authors: Bryony N Parsons; Umer Z Ijaz; Rosalinda D'Amore; Michael D Burkitt; Richard Eccles; Luca Lenzi; Carrie A Duckworth; Andrew R Moore; Laszlo Tiszlavicz; Andrea Varro; Neil Hall; D Mark Pritchard Journal: PLoS Pathog Date: 2017-11-02 Impact factor: 6.823
Authors: Akos Varga; Jothi Dinesh Kumar; Alec W M Simpson; Steven Dodd; Peter Hegyi; Graham J Dockray; Andrea Varro Journal: Physiol Rep Date: 2017-10-16
Authors: Katie A Lloyd; Bryony N Parsons; Michael D Burkitt; Andrew R Moore; Stamatia Papoutsopoulou; Malcolm Boyce; Carrie A Duckworth; Klaire Exarchou; Nathan Howes; Lucille Rainbow; Yongxiang Fang; Claus Oxvig; Steven Dodd; Andrea Varro; Neil Hall; D Mark Pritchard Journal: Cell Mol Gastroenterol Hepatol Date: 2020-01-28
Authors: Patricia Mjønes; Ivar S Nordrum; Øystein Sørdal; Liv Sagatun; Reidar Fossmark; Arne Sandvik; Helge L Waldum Journal: Horm Cancer Date: 2017-10-04 Impact factor: 3.869